Zolbetuximab for untreated HER2-negative, claudin-18.2-positive, unresectable advanced gastric or gastroesophageal junction adenocarcinoma

Published on 06 Feb 2026
Last Updated on 06 Feb 2026

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has not recommended zolbetuximab, in combination with chemotherapy, for inclusion on the MOH List of Subsidised Drugs for untreated HER2-negative, claudin-18.2-positive, unresectable advanced gastric or gastroesophageal junction adenocarcinoma. The decision was based on the unfavourable cost effectiveness of zolbetuximab plus chemotherapy compared with alternative treatments, and the unacceptable price-volume agreement proposed by the company.

Clinical indication, subsidy class and MediShield Life claim limit for zolbetuximab plus chemotherapy are provided in the Annex.

Guidance_Zolbetuximab for untreated HER2-negative, claudin-18.2-positive, unresectable advanced gastric or gastroesophageal junction adenocarcinoma (6 Feb 2026)

PES_Zolbetuximab for untreated HER2-negative, claudin-18.2-positive, unresectable advanced gastric cancer (6 Feb 2026)